Viewing StudyNCT00240253



Ignite Creation Date: 2024-05-05 @ 12:07 PM
Last Modification Date: 2024-10-26 @ 9:20 AM
Study NCT ID: NCT00240253
Status: COMPLETED
Last Update Posted: 2015-03-31
First Post: 2005-10-14

Brief Title: A Study Evaluating the Efficacy and Safety of Adding Symlin to Lantus Insulin Glargine in Subjects With Type 2 Diabetes
Sponsor: AstraZeneca
Organization: AstraZeneca

Conditions & Keywords Data

Conditions:
Name
Type 2 Diabetes Mellitus
Keywords:
Name View
insulin glargine View
diabetes View
Amylin View
Symlin View
pramlintide View